K Julia Kaal1,2, Nick Bansback2,3, Marie Hudson4, Aslam Anis2,3, Cheryl Koehn5, Mark Harrison6,7,8. 1. Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. 2. School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada. 3. St. Paul's Hospital, 1081 Burrard St, Vancouver, BC, V6Z 1Y6, Canada. 4. Division of Rheumatology, Jewish General Hospital and Lady Davis Institute, and Department of Medicine, McGill University, Montreal, QC, Canada. 5. Arthritis Consumer Experts/JointHealth, Vancouver, Canada. 6. Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. mark.harrison@ubc.ca. 7. St. Paul's Hospital, 1081 Burrard St, Vancouver, BC, V6Z 1Y6, Canada. mark.harrison@ubc.ca. 8. Arthritis Research Canada, Richmond, Canada. mark.harrison@ubc.ca.
Abstract
OBJECTIVE: To examine the perceived importance and frequency with which out-of-pocket medication costs are discussed between rheumatologists and patients with rheumatoid arthritis (RA) in Canada. METHODS: A cross-sectional online survey was distributed to patients with RA and rheumatologists; both were asked to rate their perceived importance of discussing medication costs, and how often these discussions occurred. Predictors of (1) patients discussing costs with their rheumatologist and (2) the perceived importance of discussing medication cost for patients were explored. RESULTS: Seventy-eight patients and 64 rheumatologists completed the survey; 68% patients and 75% of physicians rated the perceived importance of discussing medication costs as "quite" or "very important"; 22% of patients reported never talking about medication cost, but no physicians reported never discussing costs with patients. The only predictor of talking about cost among patients (at 10% level) was whether they perceived it as highly important (p = 0.058). Higher perceived importance of discussing out-of-pocket costs was associated with a more positive attitude to shared decision-making (p = 0.044). CONCLUSION: Discussions about cost do not always happen, even with diseases with potentially high medication costs like RA. Cost was more likely to be discussed by patients who perceived it as "very important," suggesting the onus might be on patients to initiate these conversations. Without any significant predictors regarding what may make physicians more likely to think it was important to discuss medication costs, there is a need to reinforce recommendations that all physicians seek to discuss costs with all of their patients when suggesting medications. Key Points • There is a need for patients and physicians to discuss costs in the treatment decision-making process. Our findings suggest this does not always happen. • Among patients, medication cost was more likely to be discussed by those who perceived it as "very important" and higher perceived importance of discussing out-of-pocket costs was associated with a more positive attitude to shared decision-making. • Our results did not reveal any significant predictors regarding what may make physicians more likely to think it was important to discuss medication costs, suggesting that there is a need to reinforce recommendations that all physicians seek to discuss medication costs with all of their patients when suggesting medications.
OBJECTIVE: To examine the perceived importance and frequency with which out-of-pocket medication costs are discussed between rheumatologists and patients with rheumatoid arthritis (RA) in Canada. METHODS: A cross-sectional online survey was distributed to patients with RA and rheumatologists; both were asked to rate their perceived importance of discussing medication costs, and how often these discussions occurred. Predictors of (1) patients discussing costs with their rheumatologist and (2) the perceived importance of discussing medication cost for patients were explored. RESULTS: Seventy-eight patients and 64 rheumatologists completed the survey; 68% patients and 75% of physicians rated the perceived importance of discussing medication costs as "quite" or "very important"; 22% of patients reported never talking about medication cost, but no physicians reported never discussing costs with patients. The only predictor of talking about cost among patients (at 10% level) was whether they perceived it as highly important (p = 0.058). Higher perceived importance of discussing out-of-pocket costs was associated with a more positive attitude to shared decision-making (p = 0.044). CONCLUSION: Discussions about cost do not always happen, even with diseases with potentially high medication costs like RA. Cost was more likely to be discussed by patients who perceived it as "very important," suggesting the onus might be on patients to initiate these conversations. Without any significant predictors regarding what may make physicians more likely to think it was important to discuss medication costs, there is a need to reinforce recommendations that all physicians seek to discuss costs with all of their patients when suggesting medications. Key Points • There is a need for patients and physicians to discuss costs in the treatment decision-making process. Our findings suggest this does not always happen. • Among patients, medication cost was more likely to be discussed by those who perceived it as "very important" and higher perceived importance of discussing out-of-pocket costs was associated with a more positive attitude to shared decision-making. • Our results did not reveal any significant predictors regarding what may make physicians more likely to think it was important to discuss medication costs, suggesting that there is a need to reinforce recommendations that all physicians seek to discuss medication costs with all of their patients when suggesting medications.
Authors: Deirdre Hennessy; Claudia Sanmartin; Paul Ronksley; Rob Weaver; Dave Campbell; Braden Manns; Marcello Tonelli; Brenda Hemmelgarn Journal: Health Rep Date: 2016-06-15 Impact factor: 4.796
Authors: Olivia K Richards; Bradley E Iott; Tammy R Toscos; Jessica A Pater; Shauna R Wagner; Tiffany C Veinot Journal: J Am Med Inform Assoc Date: 2022-05-11 Impact factor: 7.942
Authors: Magda Aguiar; Mark Harrison; Sarah Munro; Tiasha Burch; K Julia Kaal; Marie Hudson; Nick Bansback; Tracey-Lea Laba Journal: Patient Date: 2021-07 Impact factor: 3.883
Authors: Karalyn A Kiessling; Bradley E Iott; Jessica A Pater; Tammy R Toscos; Shauna R Wagner; Laura M Gottlieb; Tiffany C Veinot Journal: JAMIA Open Date: 2022-02-24